Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
Medtronic reported first-quarter fiscal 2027 results with broad-based growth across its largest franchises and new growth platforms, and raised its fiscal 2027 guidance. The company points to recent portfolio investments as supporting a longer-term growth trajectory, setting a higher bar for the rest of the fiscal year.
Medtronic's fiscal first-quarter 2027 report, released Tuesday from its Galway, Ireland base, showed the company's full-year revenue run rate at $36.4 billion, up 8.4% year over year, alongside diluted earnings per share of $3.73. The company characterized the quarter as one of broad-based portfolio performance, meaning growth was not concentrated in a single device category but spread across its largest franchises as well as newer growth platforms that management has been building out through recent acquisitions and internal investment. On the back of this performance, Medtronic raised its guidance for the full fiscal 2027 year, signaling management's confidence that the current growth rate is durable rather than a one-quarter anomaly.
The update comes against a backdrop in which Medtronic has spent several years working to diversify beyond its legacy cardiac and spine businesses, investing in areas such as diabetes technology, robotic-assisted surgery, and renal denervation. Prior quarters have shown the company narrating a story of gradual margin and growth improvement as newer platforms scale, and today's report appears to extend that narrative with an actual guidance raise rather than just a reaffirmation. That distinction matters: reaffirming guidance signals stability, while raising it signals that management sees more evidence than the market had already priced in.
The mechanism connecting the headline to Medtronic's shareholders is straightforward: an 8.4% year-over-year revenue growth rate, if sustained, flows through a large, relatively fixed-cost medtech manufacturing and R&D base, which can produce operating leverage and support the higher guidance. The
MDT's guidance raise on 8.4% revenue growth and $3.73 diluted EPS shifts the near-term evidence toward the bull case for the stock.
A guidance raise off broad-based growth (8.4% YoY revenue, $3.73 diluted EPS) is a rare positive datapoint for a large-cap medtech name that has spent years defending a slow-growth narrative, and it tends to reset sell-side numbers higher into the next print. The read is grounded in the filed figures rather than sentiment, which supports a modest long bias without demanding an aggressive target.
Medtech names carry tariff, FX, and device-recall tail risk that can quickly offset topline momentum; a strong quarter does not immunize against a subsequent product-specific setback.
CoverageSource: PR Newswire · Published here TUE, SEP 1 · 6:45 AM ET · the only report in this recordHow this is decided →
PR NEWSWIRE / FILEEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
An 8.4% YoY revenue growth rate paired with a full-year guidance raise suggests newer platforms (diabetes, surgical robotics, renal denervation) are scaling faster than the market had modeled, which could justify further estimate revisions.
Medtronic has repeatedly guided cautiously in the past only to see margin execution lag revenue growth, so a single strong quarter and raise does not guarantee the higher bar holds through the full fiscal year.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →